Cargando…
Cost-effectiveness of sofosbuvir in the treatment of patients with hepatitis C
In France, 190 306 patients were suffering from chronic hepatitis C in 2012. These patients have a decreased life expectancy and are susceptible to complications associated with chronic hepatitis. Current treatments are poorly tolerated and their effectiveness varies depending on the genotype of the...
Autores principales: | Leleu, H, Blachier, M, Rosa, I |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4406130/ https://www.ncbi.nlm.nih.gov/pubmed/25219291 http://dx.doi.org/10.1111/jvh.12311 |
Ejemplares similares
-
Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US
por: Zhang, Sai, et al.
Publicado: (2015) -
Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany
por: Stahmeyer, Jona T., et al.
Publicado: (2017) -
Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus
por: McEwan, Phil, et al.
Publicado: (2017) -
Cost-Effectiveness Analysis of Sofosbuvir Compared to Current Standard Treatment in Swiss Patients with Chronic Hepatitis C
por: Pfeil, Alena M., et al.
Publicado: (2015) -
Sofosbuvir-based Regimens with Task Shifting Is Cost-effective in Expanding Hepatitis C Treatment Access in the United States
por: Jayasekera, Channa R., et al.
Publicado: (2017)